Major Prostate Cancer Trial: Short HT Best in Middle RiskMajor Prostate Cancer Trial: Short HT Best in Middle Risk
Investigators hypothesized that extending the period of neoadjuvant hormone therapy (HT) would improve outcomes. They were wrong. Medscape Medical News
ConclusionsProton beam radiotherapy for prostate cancer is feasible with a low rate of acute toxicity and promising late toxicity and effectivity.
CONCLUSIONS: Being overweight was associated with positive margins in patients with PCa undergoing RP after NHT. PMID: 31451070 [PubMed - as supplied by publisher]
Abstract OBJECTIVE: Docetaxel has been shown to be an effective chemotherapy agent when combined with androgen deprivation therapy for hormone sensitive metastatic prostate cancer (CaP). Since very high risk CaP has a high rate of occult metastatic disease and early recurrence, we hypothesize that patients with very high risk locally advanced CaP may benefit from docetaxel-based neoadjuvant chemohormonal therapy (NCHT). Thus, we conducted a retrospective study to identify the outcome of these patients treated with NCHT followed by radical prostatectomy (RP). PATIENTS AND METHODS: We retrospectively analyzed d...
Condition: Advanced Prostate Cancer Intervention: Drug: Zoladex and Casodex Sponsor: AstraZeneca Not yet recruiting
Neoadjuvant hormone therapy (NHT) when given to men receiving radiation therapy (RT) for prostate cancer is known to affect long term testosterone (T) levels. Men with suppressed T may experience a lower PSA value which could influence biochemical failure determinations. We sought to determine which factors influenced the last measured T and PSA values and the relationship between the two.
CONCLUSION: Neoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable pathologic responses in some patients, with a trend toward improved pathologic outcomes with ELAP. Longer follow-up is necessary to evaluate the impact of therapy on recurrence rates. The potential association of ERG and PTEN alterations with worse outcomes warrants additional investigation. PMID: 30811282 [PubMed - as supplied by publisher]
BJU International, EarlyView.
CONCLUSIONS: An ANN-based model was developed to predict LFI. The model was translated in a "ready to use" graphical-tool for LFI risk classification, with a direct interpretation of the role of the predictors. PMID: 30092335 [PubMed - as supplied by publisher]
BJU International,Volume 0, Issue ja, -Not available-.
AbstractBackgroundThe effectiveness of cancer control is unclear after radical prostatectomy for patients with clinical T3 prostate cancer.MethodsWe retrospectively reviewed 1409 patients who underwent radical prostatectomy between April 2007 and December 2014, including 210 patients with cT3 prostate cancer. Nine patients who received neoadjuvant hormonal therapy and three patients who were lost to follow-up were excluded from the analysis. Clinical staging was performed by an experienced radiologist using preoperative magnetic resonance imaging findings. We analyzed the predictors of biochemical recurrence using Cox prop...